Dose Ranging Study

Phase,treatment,studies,trial,drugs,disease,clinical trials,Dose-Ranging Study,participant,study protocol,outcome,events,healthy volunteers,primary outcome measure,criteria.

Life,exclusion criteria,product,statistical analysis plan,Institutional review boards,observational study,interventional study,secondary outcomes,interventions,inclusion criteria,Food and Drug Administration,quality of life,biological products,location.

Issues,public health,study sponsor,Participating in Studies,study arm,study completion,study records,study research staff,submission of study results,Ages Eligible for Study,clinical study record,closed studies,health outcomes,secondary outcome measure.

Biomedical or health-related outcomes,type of intervention model,surgical intervention,behavioral interventions,types of interventions,combinations of interventions,participant in danger,subgroup of participants,type of eligibility criteria,quality control review criteria,age group requirements,antidepressant treatment,clinical trial arm,clinical trial design strategy,FDA-defined phases,initial phase,U.S. Food and Drug Administration,active drug,normal life functions,Centers for Disease Control and Prevention,Medical events,search feature,Advanced Search,search results list,studies with locations,location countries,device,trials of devices,medical device,Major issues,Advisory issues,current hospital,access status,access to registration,access types,United States,8-digit number,identification code,responsible party,congenital anomaly,birth defect,inactive substance,scientific integrity,structured online,scientific validity,academic journal,active comparator arm,associations with exposures,basic science,biological distinctions,arm type,QC review,primary completion,study design,adverse events,rates,North Carolina,regimens,single dose,optimal dose,investigational product,pulmonary disease,lateral sclerosis,Czech Republic,primary efficacy outcome,Percentage of participants,clinical investigation participant,High-dose plus AS03 group,low-dose plus AF03 group,low-dose plus AS03 group,high-dose plus AF03 group,treatment period,reference treatments,Induction Phase,elimination half life,medicinal product,candidate 3-day regimens,2-day regimens,cure rates,response rate,days of hospital observation,hospital,analysis window,analysis population.